Shukra Pharmaceuticals Limited
SHUKRAPHAR · ISIN: INE551C01044
Shukra Pharmaceuticals Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE551C01044.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Shukra Pharmaceuticals Limited - growth of ₹100
Growth of ₹100 invested on 2026-08-14, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
+20.89%
3M
-
6M
-
1Y
-
3Y CAGR
-
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Shukra Pharmaceuticals Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-10-29 | BULK | 26,92,287 |
| 2026-10-29 | BULK | 26,99,471 |
| 2026-10-23 | BULK | 34,27,223 |
| 2026-10-23 | BULK | 33,69,454 |
| 2026-10-05 | BULK | 37,00,565 |
| 2026-10-05 | BULK | 33,95,277 |
| 2026-10-05 | BULK | 29,60,423 |
| 2026-10-05 | BULK | 31,62,310 |
| 2026-10-05 | BULK | 29,60,423 |
| 2026-10-05 | BULK | 31,07,889 |
Frequently asked questions
What is Shukra Pharmaceuticals Limited's latest financial performance?
Shukra Pharmaceuticals Limited's trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹75 Cr, with a TTM profit after tax of ₹34 Cr and an EBITDA margin of null%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹0.78.
What do Shukra Pharmaceuticals Limited's technical indicators show?
As of 2026-10-29, Shukra Pharmaceuticals Limited's RSI (14-day) is 71.12 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in overbought territory. These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Shukra Pharmaceuticals Limited?
As of 2026-06-30, Shukra Pharmaceuticals Limited's shareholding is split across Promoter (51.15%), Public (48.85%). Promoter holding of 51.15% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Has Shukra Pharmaceuticals Limited seen any recent bulk or block deals?
Yes, as of 2026-10-29 - the most recent recorded deal was a BULK on 2026-10-29 for 26,92,287 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns